- Home
- ACON vs APVO Comparison
ACON vs APVO Comparison
Compare ACON & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACON
- APVO
- Stock Information
- Founded
- ACON 2008
- APVO 2016
- Country
- ACON United States
- APVO United States
- Employees
- ACON N/A
- APVO N/A
- Industry
- ACON Retail: Computer Software & Peripheral Equipment
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- ACON Technology
- APVO Health Care
- Exchange
- ACON Nasdaq
- APVO Nasdaq
- Market Cap
- ACON 4.5M
- APVO 4.9M
- IPO Year
- ACON 2022
- APVO N/A
- Fundamental
- Price
- ACON $7.80
- APVO $1.86
- Analyst Decision
- ACON Buy
- APVO Strong Buy
- Analyst Count
- ACON 2
- APVO 1
- Target Price
- ACON $481.00
- APVO $5,920.00
- AVG Volume (30 Days)
- ACON 8.1K
- APVO 6.1M
- Earning Date
- ACON 11-13-2025
- APVO 11-06-2025
- Dividend Yield
- ACON N/A
- APVO N/A
- EPS Growth
- ACON N/A
- APVO N/A
- EPS
- ACON N/A
- APVO N/A
- Revenue
- ACON $62,948.00
- APVO N/A
- Revenue This Year
- ACON $145.39
- APVO N/A
- Revenue Next Year
- ACON $145.45
- APVO N/A
- P/E Ratio
- ACON N/A
- APVO N/A
- Revenue Growth
- ACON 16.68
- APVO N/A
- 52 Week Low
- ACON $6.20
- APVO $1.32
- 52 Week High
- ACON $3,499.51
- APVO $381.10
- Technical
- Relative Strength Index (RSI)
- ACON 63.90
- APVO 50.74
- Support Level
- ACON $7.00
- APVO $1.32
- Resistance Level
- ACON $7.84
- APVO $2.71
- Average True Range (ATR)
- ACON 0.28
- APVO 0.25
- MACD
- ACON 0.07
- APVO 0.06
- Stochastic Oscillator
- ACON 96.09
- APVO 38.12
About ACON Aclarion Inc.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.